Linaclotide Side Effects: Safety Signals and Warnings
Linaclotide safety concerns are compound-specific. The main listed side effects are Diarrhea (most common, up to 20% at higher doses), Abdominal pain, and Flatulence. The main warning signals are Contraindicated in children under 2 years (risk of serious dehydration and death in neonatal mice), Avoid in patients 2 to less than 18 years old, and Contraindicated in known or suspected mechanical GI obstruction.
Direct Answer
Linaclotide (Linzess) is FDA-approved for IBS-C and chronic idiopathic constipation, with robust Phase 3 data across multiple trials. It is one of the most prescribed GI peptide drugs in the US, with real-world data supporting its Phase 3 results. For guanylate cyclase-C agonism and IBS-C research, linaclotide is the established reference compound.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- IBS-C, chronic idiopathic constipation, guanylate cyclase-C agonism, visceral pain modulation
Reported Side Effects
- Diarrhea (most common, up to 20% at higher doses)
- Abdominal pain
- Flatulence
- Abdominal distension
- Upper respiratory tract infection
- Sinusitis
- Fecal incontinence (rare)
Warnings
- Contraindicated in children under 2 years (risk of serious dehydration and death in neonatal mice)
- Avoid in patients 2 to less than 18 years old
- Contraindicated in known or suspected mechanical GI obstruction
- Discontinue if severe diarrhea develops
- Take on empty stomach for optimal absorption
Known or Plausible Interactions
- Minimal systemic drug interactions due to local GI mechanism
- Other GC-C agonists (avoid concurrent use with plecanatide)
- Proton pump inhibitors (may alter local pH and affect peptide stability)
Regulatory Context
FDA-approved (Linzess) since August 2012 for IBS-C and CIC. Marketed as Constella in Europe (EMA-approved 2012). Prescription required. Available worldwide in multiple markets.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | IBS-C Symptom Relief (Level A), Chronic Idiopathic Constipation Relief (Level A), Visceral Pain Reduction (Level A), and Diarrhea (Adverse) (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Linaclotide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/linaclotide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.